Enlivex Therapeutics Ltd. – NASDAQ:ENLV

Add to watchlist

$1.06

-0.12

-10.92%

Market open

Closed in about 2 hours

-19.59%

month

-19.59%

quarter

-57.50%

year

Market Cap	27.03M
Enterprise value	N/A

P/E	-2.15
EV/Sales	N/A
EV/EBITDA	0.03
Price/Sales	N/A
Price/Book	0.81
PEG ratio	0.09
EPS	-1.4

Revenue	N/A
EBITDA	-21.50M
Income	-25.99M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Enlivex Therapeutics Ltd. (NASDAQ:ENLV): Profit margin
Jun 2023	0	-6.79M
Sep 2023	0	-5.96M
Dec 2023	0	-9.09M
Mar 2024	0	-4.14M

Enlivex Therapeutics Ltd. Financials Estimate

Q Y

Enlivex Therapeutics Ltd. (NASDAQ:ENLV): Analyst Estimates
Dec 2023	0	-9.09M
Mar 2024	0	-4.14M
Sep 2025	0	-2.80M
Dec 2025	0	-2.43M

Analysts Price target
Financials & Ratios estimates

Enlivex Therapeutics Ltd. (NASDAQ:ENLV): Earnings per share (EPS)
2022-08-22	-0.45	-0.54
2022-12-05	-0.29	-0.31

Enlivex Therapeutics Ltd. (NASDAQ:ENLV): Debt to assets
Jun 2023	53028000	8.69M	16.39%
Sep 2023	46936000	8.15M	17.38%
Dec 2023	36831000	6.74M	18.32%
Mar 2024	31047000	4.19M	13.51%

Enlivex Therapeutics Ltd. (NASDAQ:ENLV): Cash Flow
Jun 2023	-7.02M	-2.70M	42K
Sep 2023	-5.43M	3.94M	-5.56K
Dec 2023	-5.02M	4.09M	-1.28K
Mar 2024	-4.51M	5.09M	524K

Enlivex Therapeutics Ltd. alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Enlivex Therapeutics Ltd.
Employees

Enlivex Therapeutics Ltd. (NASDAQ:ENLV): Employee count
Aug 2023	71
Sep 2023	71
Oct 2023	71
Nov 2023	71
Dec 2023	71
Jan 2024	71
Feb 2024	71
Mar 2024	71
Apr 2024	71
May 2024	71
Jun 2024	71
Jul 2024	71

Enlivex Therapeutics Ltd.
Hedge Funds Holdings Q1 2023

1.21% -0.63%

of ENLV is owned by hedge funds

11 -9

hedge funds hold ENLV stock

222.15K -115.70K

shares is hold by hedge funds

ENLV hedge funds holdings changes

Enlivex Therapeutics Ltd.
Patents

Status	Patent	Filling date	Issue date
Application	Application COMBINATION IMMUNE THERAPY AND CYTOKINE CONTROL THERAPY FOR CANCER TREATMENT Filling date: 4 Jan 2022 Issue date: 5 May 2022	4 Jan 2022	5 May 2022
Grant	Grant Utility: Combination immune therapy and cytokine control therapy for cancer treatment Filling date: 4 Nov 2019 Issue date: 3 May 2022	4 Nov 2019	3 May 2022
Grant	Grant Utility: Combination immune therapy and cytokine control therapy for cancer treatment Filling date: 19 Nov 2018 Issue date: 19 Apr 2022	19 Nov 2018	19 Apr 2022
Application	Application COMBINATION IMMUNE THERAPY AND CYTOKINE CONTROL THERAPY FOR CANCER TREATMENT Filling date: 5 Apr 2021 Issue date: 29 Jul 2021	5 Apr 2021	29 Jul 2021
Grant	Grant Utility: Combination immune therapy and cytokine control therapy for cancer treatment Filling date: 24 Aug 2017 Issue date: 11 May 2021	24 Aug 2017	11 May 2021
Application	Application COMBINATION IMMUNE THERAPY AND CYTOKINE CONTROL THERAPY FOR CANCER TREATMENT Filling date: 24 Aug 2017 Issue date: 15 Apr 2021	24 Aug 2017	15 Apr 2021
Grant	Grant Utility: Therapeutic apoptotic cell preparations, method for producing same and uses thereof Filling date: 29 Jul 2018 Issue date: 23 Feb 2021	29 Jul 2018	23 Feb 2021
Application	Application THERAPEUTIC POOLED BLOOD APOPTOTIC CELL PREPARATIONS AND USES THEREOF Filling date: 21 Oct 2020 Issue date: 11 Feb 2021	21 Oct 2020	11 Feb 2021
Grant	Grant Utility: Therapeutic pooled blood apoptotic cell preparations and uses thereof Filling date: 21 Apr 2016 Issue date: 8 Dec 2020	21 Apr 2016	8 Dec 2020
Application	Application EARLY APOPTOTIC CELLS FOR USE IN TREATING SEPSIS Filling date: 28 May 2020 Issue date: 17 Sep 2020	28 May 2020	17 Sep 2020

ENLV patents

Enlivex Therapeutics Ltd.
Executives

Insider	Age	Compensation
Mr. Shai Novik M.B.A. (1966) Executive Chairman	59	$528,000
Dr. Oren Hershkovitz Ph.D. (1977) Chief Executive Officer	48	$273,600
Prof. Dror Mevorach M.D. (1956) Founder and Chief Scientific & Medical Officer	69	$180,000
Ms. Shachar Shlosberger CPA (1977) Chief Financial Officer	48	$126,000

Enlivex Therapeutics Ltd.
Latest News

Wednesday, 11 December 2024
08:30	Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis	globenewswire.com
Thursday, 5 December 2024
10:49	Enlivex Announces Positive Interim Efficacy Data from Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis	globenewswire.com
Tuesday, 3 December 2024
08:30	Enlivex Announces Positive Interim Efficacy Data from Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis	https://www.globenewswire.com/
Tuesday, 26 November 2024
10:15	Join Enlivex Therapeutics' Exclusive Live Investor Webinar and Q&A Session on December 3	accesswire.com
Thursday, 14 November 2024
08:00	Enlivex Announces the Dosing of the First Patient in a Phase I Clinical Trial Evaluating Allocetra in Patients with Psoriatic Arthritis	globenewswire.com
Thursday, 31 October 2024
13:00	Enlivex Therapeutics (ENLV) Upgraded to Strong Buy: Here's What You Should Know	zacks.com
Wednesday, 30 October 2024
08:00	Enlivex Receives Notice of Allowance for Japanese Patent Application Covering the Use of Allocetra™ in Patients with Osteoarthritis	globenewswire.com
Wednesday, 23 October 2024
08:20	New Strong Buy Stocks for October 23rd	zacks.com
Tuesday, 24 September 2024
08:30	Enlivex Announces Positive DSMB Recommendation to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis	globenewswire.com
Wednesday, 11 September 2024
13:00	All You Need to Know About Enlivex Therapeutics (ENLV) Rating Upgrade to Buy	zacks.com
Friday, 30 August 2024
09:00	GreenPower and Enlivex Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV	accesswire.com
Friday, 19 July 2024
09:00	Enlivex Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV	accesswire.com
Monday, 17 June 2024
08:00	Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee Osteoarthritis	globenewswire.com
Wednesday, 29 May 2024
16:15	Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering	globenewswire.com
Tuesday, 28 May 2024
08:12	Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering	globenewswire.com
Tuesday, 16 April 2024
07:50	Enlivex Announces Authorization from the Danish Regulatory Agency for the Company's Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis	globenewswire.com
Monday, 15 April 2024
14:05	Enlivex (ENLV) Stock Plummets 51% in a Week: Here's Why	Zacks Investment Research
Thursday, 11 April 2024
14:58	Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with Sepsis	GlobeNewsWire
Friday, 3 November 2023
09:02	New Strong Buy Stocks for November 3rd	Zacks Investment Research
Friday, 27 October 2023
07:31	New Strong Buy Stocks for October 27th	Zacks Investment Research
Thursday, 19 October 2023
08:16	New Strong Buy Stocks for October 19th	Zacks Investment Research
Tuesday, 6 June 2023
08:00	Enlivex to Present at the 2023 Jefferies Healthcare Conference	GlobeNewsWire
Monday, 3 October 2022
08:13	Enlivex to Present at the 4th Macrophage-Directed Therapies Summit	GlobeNewsWire
Friday, 30 September 2022
02:08	Enlivex Therapeutics: A Very Enticing Early-Stage Biotech	Seeking Alpha
Tuesday, 7 June 2022
08:00	Enlivex to Present at the 2022 Jefferies Healthcare Conference	GlobeNewsWire
Monday, 6 December 2021
10:48	Enlivex Therapeutics Stock (ENLV): Why The Price Increased Today	Pulse2
Tuesday, 12 October 2021
08:00	Enlivex CSO Prof. Dror Mevorach Publishes Foundational Paper on the Pfizer–BioNTech COVID-19 Vaccine in The New England Journal of Medicine	GlobeNewsWire
Wednesday, 29 September 2021
08:48	Enlivex to Present at Reuters Events' Cell & Gene Therapy USA 2021	GlobeNewsWire
Monday, 27 September 2021
07:45	Enlivex Therapeutics (ENLV) Sees Hammer Chart Pattern: Time to Buy?	Zacks Investment Research
Thursday, 23 September 2021
11:27	Enlivex (ENLV) Begins Phase IIb COVID-19 Study on Cell Therapy	Zacks Investment Research

Ideas & Opinions

Seeking Alpha 30 Sep 2022

Enlivex Therapeutics: A Very Enticing Early-Stage Biotech
Seeking Alpha 19 Aug 2021

Why Co-Diagnostics Is A Solid Covid-19 Play
Seeking Alpha 29 Mar 2021

Enlivex: Interesting Macrophage Reprogramming Science Targets $33B Sepsis Market

Frequently Asked Questions (FAQ)

What's the price of Enlivex Therapeutics Ltd. stock today?

One share of Enlivex Therapeutics Ltd. stock can currently be purchased for approximately $1.06.
When is Enlivex Therapeutics Ltd.'s next earnings date?

Unfortunately, Enlivex Therapeutics Ltd.'s (ENLV) next earnings date is currently unknown.
Does Enlivex Therapeutics Ltd. pay dividends?

No, Enlivex Therapeutics Ltd. does not pay dividends.
How much money does Enlivex Therapeutics Ltd. make?

Enlivex Therapeutics Ltd. has a market capitalization of 27.03M. Enlivex Therapeutics Ltd. made a loss 29.07M US dollars in net income (profit) last year or -$0.31 on an earnings per share basis.
What is Enlivex Therapeutics Ltd.'s stock symbol?

Enlivex Therapeutics Ltd. is traded on the NASDAQ under the ticker symbol "ENLV".
What is Enlivex Therapeutics Ltd.'s primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Enlivex Therapeutics Ltd.?

Shares of Enlivex Therapeutics Ltd. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Enlivex Therapeutics Ltd.'s key executives?
Enlivex Therapeutics Ltd.'s management team includes the following people:
- Mr. Shai Novik M.B.A. Executive Chairman(age: 59, pay: $528,000)
- Dr. Oren Hershkovitz Ph.D. Chief Executive Officer(age: 48, pay: $273,600)
- Prof. Dror Mevorach M.D. Founder and Chief Scientific & Medical Officer(age: 69, pay: $180,000)
- Ms. Shachar Shlosberger CPA Chief Financial Officer(age: 48, pay: $126,000)
Is Enlivex Therapeutics Ltd. founder-led company?

Yes, Enlivex Therapeutics Ltd. is a company led by its founder Prof. Dror Mevorach M.D..
How many employees does Enlivex Therapeutics Ltd. have?

As Jul 2024, Enlivex Therapeutics Ltd. employs 71 workers.
When Enlivex Therapeutics Ltd. went public?

Enlivex Therapeutics Ltd. is publicly traded company for more then 11 years since IPO on 31 Jul 2014.
What is Enlivex Therapeutics Ltd.'s official website?

The official website for Enlivex Therapeutics Ltd. is enlivex.com.
How can i contact Enlivex Therapeutics Ltd.?

Enlivex Therapeutics Ltd. can be reached via phone at +972 8 662 3301.

Enlivex Therapeutics Ltd.

enlivex.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.

+972 8 662 3301

14 Einstein Street
Ness Ziona, 7403618

CIK: 0001596812
ISIN: IL0011319527
CUSIP: M4130Y106